These aren't easy times for biotech, but that's not exactly news to investors in that sector. Neurocrine Biosciences (NASDAQ:NBIX) has gotten caught up in the sector-wide funk, though the shares have declined less since my last update than the biotech indices.
Neurocrine
still looks promising to me. There are significant uncertainties about
potential pricing for the company's lead drugs, not to mention the
amount of effort that will have to go into building prescription-driving
awareness. That said, this is still a company with multiple compounds
with $1 billion-plus revenue potential that have largely proven their
efficacy and safety in clinical trials. With the shares possibly
undervalued by 50% or more, I would suggest this is still a worthwhile
stock to consider for aggressive investors willing to put up with the
risks and long waits that go with biotech.
Follow the link to read more:
Uncertainties And Wait Times Not Helping Neurocrine Biosciences
No comments:
Post a Comment